BRPI0507363A - métodos para manufatura de 1,3-dioxolano nucleosìdeos - Google Patents

métodos para manufatura de 1,3-dioxolano nucleosìdeos

Info

Publication number
BRPI0507363A
BRPI0507363A BRPI0507363-4A BRPI0507363A BRPI0507363A BR PI0507363 A BRPI0507363 A BR PI0507363A BR PI0507363 A BRPI0507363 A BR PI0507363A BR PI0507363 A BRPI0507363 A BR PI0507363A
Authority
BR
Brazil
Prior art keywords
dioxolane
lactone
substantially pure
nucleoside
manufacturing
Prior art date
Application number
BRPI0507363-4A
Other languages
English (en)
Inventor
Marcos Sznaidman
George R Painter
Merrick Almond
Darryl G Cleary
Amir Pesyan
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BRPI0507363A publication Critical patent/BRPI0507363A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MéTODOS PARA MANUFATURA DE 1,3-DIOXOLANO NUCLEOSìDEOS Esse pedido fornece um processo para a preparação de <225>-D-dioxolano nucleosídeos enantiomericamente puros. Em particular, uma nova síntese, de (-)-DAPD, adequada para desenvolvimento em ampla escala, é descrita. Em uma modalidade a invenção fornece um processo para a preparação de <225>-D ou <225>-L-1,3-dioxolano nucleosídeos substancialmente puros que compreende a) a preparação ou obtenção de um 2,2-di-alcoxi etanol esterificado; b) ciclização do 2,2-dialcoxi etanol esterificado com ácido glicólico para obter uma 1,3-dioxolano lactona; c) separação da 1,3-dioxolano lactona para obter uma D- ou L-lactona substancialmente pura; d) redução seletiva e ativação da D-ou L-lactona quiral para obter um D- ou L-1,3-dioxolano substancialmente puro; e) ligação do D- ou L-1,3-dioxolano a uma base de purina ou pirimidina ativada e/ou protegida; e f) purificação opcional do nucleosídeo para obter um <225>-D ou <225>-L-1,3-dioxolano nucleosídeo protegido substancialmente puro.
BRPI0507363-4A 2004-02-03 2005-02-03 métodos para manufatura de 1,3-dioxolano nucleosìdeos BRPI0507363A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54154504P 2004-02-03 2004-02-03
PCT/US2005/003620 WO2005074654A2 (en) 2004-02-03 2005-02-03 Methods to manufacture 1,3-dioxolane nucleosides

Publications (1)

Publication Number Publication Date
BRPI0507363A true BRPI0507363A (pt) 2007-07-03

Family

ID=34837503

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507363-4A BRPI0507363A (pt) 2004-02-03 2005-02-03 métodos para manufatura de 1,3-dioxolano nucleosìdeos

Country Status (9)

Country Link
US (2) US7785839B2 (pt)
EP (1) EP1720840B1 (pt)
KR (1) KR101157468B1 (pt)
CN (2) CN105039489A (pt)
BR (1) BRPI0507363A (pt)
CA (1) CA2554782C (pt)
ES (1) ES2568467T3 (pt)
HK (1) HK1216432A1 (pt)
WO (1) WO2005074654A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085638A1 (en) * 2002-01-25 2005-04-21 Shire Biochem Inc Process for producing dioxolane nucleoside analogues
CA2554782C (en) * 2004-02-03 2013-08-13 Emory University Methods to manufacture 1,3-dioxolane nucleosides
CN105385621B (zh) * 2015-11-20 2018-10-02 浙江昌明药业有限公司 琼氏不动杆菌zjutfet-1及其应用
WO2019232067A1 (en) * 2018-05-29 2019-12-05 Centrillion Technologies, Inc. Increasing efficiency of photochemical reactions on substrates
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
JP3524606B2 (ja) * 1994-12-28 2004-05-10 三洋電機株式会社 固形製剤充填装置
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
US5792773A (en) 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
AU739240B2 (en) * 1997-03-19 2001-10-04 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
ATE292631T1 (de) 1998-08-12 2005-04-15 Gilead Sciences Inc Verfahren zu herstellung von 1,3-oxathiolane nukleosiden
MXPA01006425A (es) 1998-12-23 2002-06-04 Iaf Biochem Int Analogos de nucleosido antivirales.
CA2362570A1 (en) 1999-02-11 2000-08-17 Shire Biochem Inc. Stereoselective synthesis of nucleoside analogues
US6512845B1 (en) * 1999-07-20 2003-01-28 Canon Kabushiki Kaisha Iterative approximation of color patch area
ATE360016T1 (de) 2000-02-11 2007-05-15 Shire Biochem Inc Ein stereoselektives verfahren zur herstellung von nukleosidanalogen
AU2002212015B2 (en) * 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
US20050085638A1 (en) 2002-01-25 2005-04-21 Shire Biochem Inc Process for producing dioxolane nucleoside analogues
AU2003294212B2 (en) * 2002-08-06 2010-01-07 Pharmasset Inc. Processes for preparing 1,3-dioxolane nucleosides
CA2554782C (en) * 2004-02-03 2013-08-13 Emory University Methods to manufacture 1,3-dioxolane nucleosides

Also Published As

Publication number Publication date
US8420354B2 (en) 2013-04-16
KR101157468B1 (ko) 2012-07-06
CA2554782C (en) 2013-08-13
WO2005074654A3 (en) 2005-09-22
CA2554782A1 (en) 2005-08-18
WO2005074654A2 (en) 2005-08-18
CN101044122A (zh) 2007-09-26
US20110130559A1 (en) 2011-06-02
HK1216432A1 (zh) 2016-11-11
EP1720840A2 (en) 2006-11-15
CN105039489A (zh) 2015-11-11
KR20070085075A (ko) 2007-08-27
EP1720840A4 (en) 2009-01-21
EP1720840B1 (en) 2016-02-03
ES2568467T3 (es) 2016-04-29
US20060036092A1 (en) 2006-02-16
US7785839B2 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
Schwede et al. Cyclic nucleotide analogs as biochemical tools and prospective drugs
FI2604620T4 (fi) Modifioituja fluorinoituja nukleosidianalogeja
DE602004007620D1 (de) Lipophile derivate doppelsträngiger ribonukleinsäure
EP3109244A3 (en) Preparation of 2&#39;fluoro-2&#39;-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2008070749A3 (en) Photocleavable labeled nucleotides and nucleosides and labeled nucleotides and nucleosides and methods for their use in dna sequencing
Deninno et al. 3 ‘-Aminoadenosine-5 ‘-uronamides: Discovery of the first highly selective agonist at the human adenosine A3 receptor
BR122019020833B8 (pt) agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona
BRPI0507363A (pt) métodos para manufatura de 1,3-dioxolano nucleosìdeos
WO2000066604A3 (en) L-ribo-lna analogues
WO2005059157A3 (en) METHODS AND COMPOSITIONS FOR USE IN PREPARING HAIRPIN RNAs
BRPI0412031A (pt) sìntese de beta-l-2&#39;-deóxi-nucleosìdeos
Chun et al. Enantiomeric Syntheses of Conformationally Restricted d-and l-2 ‘, 3 ‘-Dideoxy-2 ‘, 3 ‘-endo-methylene Nucleosides from Carbohydrate Chiral Templates
HUP9801687A2 (hu) Eljárás nukleinsavak előállítására
Ishii et al. Practical synthesis of 4′-selenopurine nucleosides by combining chlorinated purines and ‘armed’4-selenosugar
BR0016162A (pt) Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos
Kozlov et al. Nonenzymatic oligomerization reactions on templates containing inosinic acid or diaminopurine nucleotide residues
Santaniello et al. Synthesis of modified purine nucleosides and related compounds mediated by adenosine deaminase (ADA) and adenylate deaminase (AMPDA)
AR057096A1 (es) Proceso para preparar acidos y lactonas sacarinicos
BR0104461A (pt) Processo seletivo para produzir um anÈmero a partir de um derivado de sacarìdeo 1-fosforilado e processo para produzir um nucleosìdeo
BRPI0515565A (pt) suporte de sìlica, catalisador de heteropoliácido produzido deste e sìntese de éster usando o catalisador de heteropoliácido suportado
JP2026511608A (ja) ヌクレオシド類似体を合成するための方法及び試薬、ならびにそれらの用途
AU2003227813A1 (en) Use of nucloeoside derivatives comprising a citrate group for producing antibodies having affinity for triphosphorylated nucleosides and uses thereof
Choi et al. Stereoselective synthesis of amino-substituted apio dideoxynucleosides through a distant neighboring group effect
Nair et al. High selectivity of novel isoguanosine analogues for the adenosine A1 receptor
BR0316336A (pt) Quantificação absoluta de ácidos nucléicos por rt-pcr

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time